Takeda received U.S. FDA approval for HYQVIA [Immune Globulin Infusion 10% (Human)] co-formulated with Halozyme’s ENHANZE drug delivery technology for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). HYQVIA was first granted FDA approval in 2014 for the treatment of primary immunodeficiency (PI) in adults, which has since been expanded to include children 2-16 years old.   HYQVIA is the only FDA-approved combination of immunoglobulin (IG) and hyaluronidase, ...